Advanced Accelerator Applications invests $6 million for Annexin research
Advanced Accelerator Applications has invested approximately $6 million in Atreus Pharmaceuticals which will be used to expand Atreus’ research in molecular imaging based on Annexin V.
Atreus, headquartered in Ottawa, develops in-vivo radiopharmaceutical products suitable for SPECT and PET imaging.
Annexin V, an endogenous human protein which binds to phosphatidylserine, labeled with technetium-99m (Tc-99m), has demonstrated the ability to image cellular apoptosis and necrosis–conditions including rheumatoid arthritis, Crohn’s disease, Alzheimer’s disease, myocarditis, cardiac transplant rejection, acute myocardial infarction and unstable atherosclerotic carotid artery disease, said Atreus.
In addition, Tc-99m labeled Annexin has been used to evaluate the response to treatment for lymphoma and lung cancer, added Atreus.
Saint Genis Pouilly, France-based Advanced Accelerator Applications said its investment will be made in stages depending on the accomplishment of certain research and regulatory milestones.
Atreus, headquartered in Ottawa, develops in-vivo radiopharmaceutical products suitable for SPECT and PET imaging.
Annexin V, an endogenous human protein which binds to phosphatidylserine, labeled with technetium-99m (Tc-99m), has demonstrated the ability to image cellular apoptosis and necrosis–conditions including rheumatoid arthritis, Crohn’s disease, Alzheimer’s disease, myocarditis, cardiac transplant rejection, acute myocardial infarction and unstable atherosclerotic carotid artery disease, said Atreus.
In addition, Tc-99m labeled Annexin has been used to evaluate the response to treatment for lymphoma and lung cancer, added Atreus.
Saint Genis Pouilly, France-based Advanced Accelerator Applications said its investment will be made in stages depending on the accomplishment of certain research and regulatory milestones.